 |
BioWorld-Insight-2002-09-16
Stock Winners and Losers For The Week
'B' Estrogen Receptor Approach Gains Ground In Breast Cancer
With the dropping of the Avastin (bevacizumab) shoe last week - Genentech Inc. disclosed Phase III data showing the breast cancer drug missed its primary efficacy endpoint - came a renewed focus not only on vascular endothelial growth factor treatments but also on the disease itself. (BioWorld Financial Watch)
Non-U.S. Clinical Trials, Regulatory Submissions, Recommendations And Approvals: August 2002
No Abstract